A Novel Transcriptome-Wide Association Study Identifies USP36 as a Potential Therapeutic Target for Heart Failure
Drug Research · 01.09.2026 · 76 (07) · 186-194
DOI: 10.1055/a-2897-9774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.09.2026. Verfasst von Kefu Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fengtai District, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, China, Beijing. Hauptthemen laut MEDLINE: Heart Failure, Transcriptome, Ubiquitin Thiolesterase. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure is a significant global health burden. This study aims to identify heart failure–associated genes through transcriptome-wide association studies combined with genome-wide association studies. A transcriptome-wide association study was conducted using Functional Summary-based Imputation, integrating heart failure genome-wide association study summary data (47,309 cases and 930,014 controls) with Genotype-Tissues Expression Project V8 expression quantitative trait loci data from 49 tissues. Gene-level analysis was performed using Multi-marker Analysis of Genomic Annotation, followed by mendelian randomization and Bayesian colocalization. The functional implications of candidate genes were explored using GeneMANIA, and the druggability of the top gene, USP36, was evaluated via molecular docking simulations. Functional Summary-based Imputation and Multi-marker Analysis of Genomic Annotation analyses identified 26 candidate genes. Further investigation highlighted USP36 as significant, particularly in left ventricular tissue, where it confers protection against heart failure. GeneMANIA showed that USP36 interacts with genes involved in oxidative stress-induced apoptosis, suggesting its role in heart failure pathogenesis. Molecular docking simulations confirmed USP36’s binding affinity with heart failure therapeutics, supporting its potential as a therapeutic target. USP36 is a novel heart failure susceptibility gene and a promising therapeutic target. Its involvement in oxidative stress-related pathways offers new insights into heart failure risk and warrants further investigation for disease development and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fengtai District, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, China, Beijing.
- Capital Medical University, College of Pharmacy, China, Beijing.
ORCID-Profile: Qiuxiao Meng, Zhigang Zhao, Li Yang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Yu, K., Meng, Q., Jiang, W., Zhao, Z., & Yang, L. (2026). A Novel Transcriptome-Wide Association Study Identifies USP36 as a Potential Therapeutic Target for Heart Failure. Drug Research, 76(07), 186-194. https://doi.org/10.1055/a-2897-9774
Vancouver
Yu K, Meng Q, Jiang W, Zhao Z, Yang L. A Novel Transcriptome-Wide Association Study Identifies USP36 as a Potential Therapeutic Target for Heart Failure. Drug Research. 2026;76(07):186-194. doi:10.1055/a-2897-9774
BibTeX
@article{Yu2026,
author = {Yu, Kefu and Meng, Qiuxiao and Jiang, Wenshuo and Zhao, Zhigang and Yang, Li},
title = {A Novel Transcriptome-Wide Association Study Identifies USP36 as a Potential Therapeutic Target for Heart Failure},
journal = {Drug Research},
year = {2026},
volume = {76},
number = {07},
pages = {186--194},
doi = {10.1055/a-2897-9774}
}
EUVIMED